The Board of Appeal (at EPO)  has been appointed. The fate of  The Cutoff Patent is being laid into the hands of the 3 experts in the following document

Board members EPO appeal

Hopefully the team of Senior investigative journalists (sic) at MedicoInvestor will be able to give you a profile of each.

Anyway – the claims have also been amended – first and foremost the awaited replacement of bodily fluids – with plasma, serum or urine

amended claims NGAL Cutoff-patent


enjoy …

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂


Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.